IL17A and rheumatoid arthritis: It is also well established that cardiovascular prognosis can be improved by targeted anti-inflammatory therapy in patients with rheumatoid arthritis (IL-6, TNF-α and IL-17A cascades) [25,26], psoriasis (IL-17/IL-23 axis) [27,28,29] and systemic lupus erythematosus (IL-17A signaling) [30] and other markers of inflammation, even beyond the inflammasome [24,31].